Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
29 hedge funds and large institutions have $75.2M invested in Sierra Oncology, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 21 closing their positions.
432% more capital invested
Capital invested by funds: $14.1M → $75.2M (+$61M)
36% less funds holding
Funds holding: 45 → 29 (-16)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
76% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$269K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$243K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$154K |
| 4 |
VF
Virtu Financial
New York
|
+$55.7K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$8.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.44M |
| 2 |
6CM
683 Capital Management
New York
|
-$1.28M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$924K |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$781K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$402K |
SRRA Hedge Fund Activity: Q4 2019 in Review
29 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q4 2019, worth a combined $75.2M — up 432% from $14.1M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of SRRA and 5 opened new positions — a net loss of 16 holders — while 8 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $269K. The largest seller was Mangrove Partners, exiting entirely with an estimated $1.44M sold.
- 29 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q4 2019, down from 45 in Q3 2019.
- Funds reported $75.2M of Sierra Oncology, Inc. Common Stock stock for Q4 2019, up 432% quarter-over-quarter.
- 5 funds opened new Sierra Oncology, Inc. Common Stock positions in Q4 2019 and 21 closed out, a net change of -16 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $269K added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q4 2019 was Mangrove Partners, an estimated $1.44M sold.
Based on aggregated 13F filings for Q4 2019.